Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
NCT06986174Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in Waldenström macroglobulinemia (WM). Started Nov 2025; status: recruiting.
02
Drugs
pacritinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06986174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986174.